Optimising Geographic Atrophy clinical trial design for faster results

The predictable pace of vision loss

Imagine your immune system is a slow-moving glacier, steadily carving away at your retina. This is Geographic Atrophy (GA). It doesn't stop, and it doesn't speed up; it grinds on at a predictable pace. Because this progression is so steady, researchers have found a way to hack the maths of Geographic Atrophy clinical trial design.

Currently, testing new drugs requires massive groups of people to account for natural variation. This makes trials expensive and sluggish. However, new research suggests that because GA grows so reliably, we can use a patient's own history to sharpen our data. By measuring the disease before the drug starts, we create a personalised baseline.

Improving Geographic Atrophy clinical trial design

Researchers used computer simulations to test how 'run-in' phases—a period of observation before treatment begins—affect trial power. By measuring the 'natural' speed of the disease in a patient first, scientists can better see if a drug actually slows it down later. The results suggest we can drastically shrink the guest list for these studies.

• A standard two-year trial requires 156 participants for high statistical confidence.
• Adding a nine-month observation period drops that requirement to just 26 people.
• A single-arm trial, where every participant receives the drug after an observation phase, requires only 14 people.

This shift could allow scientists to organise smaller, faster, and more frequent tests. It suggests that instead of waiting years for results from massive cohorts, we could identify effective treatments using a fraction of the resources. This may lead to a more efficient pipeline for vision-saving therapies without sacrificing accuracy.